BMS-P5
- Product Name
- BMS-P5
- CAS No.
- 1549811-36-0
- Chemical Name
- BMS-P5
- Synonyms
- BMS-P5 HCL;BMS-P5, 10 mM in DMSO;NET,BMS P5,myeloma,inhibit,Peptidylarginine Deiminase,Inhibitor,Protein Arginine Deiminase,Multiple,BMS-P5,BMS-P-5,BMSP5;[(2S,5R)-5-amino-2-methylpiperidin-1-yl]-[2-[1-(cyclopropylmethyl)pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methylbenzimidazol-5-yl]methanone;((2S,5S)-5-amino-2-methylpiperidin-1-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone hydrochloride
- CBNumber
- CB29731093
- Molecular Formula
- C27H33ClN6O2
- Formula Weight
- 509.05
- MOL File
- 1549811-36-0.mol
BMS-P5 Property
- form
- Solid
- color
- Off-white to light yellow
- InChIKey
- UMXWDEKCDIDCBA-TVJVWYQLNA-N
- SMILES
- C(C1CC1)N1C2=NC=CC=C2C=C1C1=NC2=CC(C(N3C[C@H](N)CC[C@@H]3C)=O)=CC(OC)=C2N1C.Cl |&1:21,25,r|
BMS-P5 Chemical Properties,Usage,Production
Description
BMS-P5 is a Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor with pIC50 values in the range of 5-?7.5. BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression Targeting PAD4 may be beneficial for treatment of multiple myeloma.
Uses
BMS-P5 is a selective and orally active peptidylarginine deiminase 4 (PAD4) inhibitor with an IC50 of 98 nM. BMS-P5 shows selective for PAD4 over PAD1, PAD2, and PAD3. BMS-P5 blocks multiple myeloma (MM)-induced neutrophil extracellular trap (NET) formation and delays progression of MM in a syngeneic mouse model[1].
Biological Activity
BMS-P5 is an inhibitor of the protein arginine deiminase 4 (PAD4; IC50 = 0.098 μM). It is selective for PAD4 over PAD1, -2, and -3 (IC50s = >10 μM). BMS-P5 (1 μM) inhibits citrullination of histone H3 and neutrophil extracellular trap (NET) formation induced by RPMI-8226- or MM.1S-conditioned medium in isolated human neutrophils. It delays disease onset and increases survival in a DP42 syngeneic mouse model of multiple myeloma when administered at a dose of 50 mg/kg.
in vivo
BMS-P5 (50 mg/kg, oral gavage) significantly improves survival of MM-bearing mice[1].
BMS-P5 (50 mg/kg, oral gavage) may attenuate the presence of pro-tumorigenic proteins in the tumor microenvironment, and thus delay tumor progression[1].
| Animal Model: | Syngeneic mouse model of MM[1]. |
| Dosage: | 50 mg/kg. |
| Administration: | Oral gavage, twice a day beginning on day 3 after tumor cell injection. |
| Result: | Significantly delayed development of symptoms and significantly prolonged survival of MM-bearing mice. |
References
[1] Marina Li, et al. A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Mol Cancer Ther. 2020 Jul;19(7):1530-1538. DOI:10.1158/1535-7163.MCT-19-1020
BMS-P5 Preparation Products And Raw materials
Raw materials
Preparation Products
BMS-P5 Suppliers
- Tel
- 18 15623560702
- info@chuchangbiotech.com
- Country
- China
- ProdList
- 162
- Advantage
- 58
- Tel
- 13764913901
- Fax
- -
- info@angtibio.com
- Country
- China
- ProdList
- 4984
- Advantage
- 55
- Tel
- 021-65675885 18964387627
- Fax
- 021-65675885
- info@efebio.com
- Country
- China
- ProdList
- 9803
- Advantage
- 58
- Tel
- 021-31433387 15618786686
- Fax
- QQ:1369748377
- sales@rechemscience.com
- Country
- China
- ProdList
- 2991
- Advantage
- 58
- Tel
- +1-2135480471
- sales@sarms4muscle.com
- Country
- China
- ProdList
- 10473
- Advantage
- 58
- Tel
- +86-0519-85788828 +86-13775037613
- sales@chemrenpharm.com
- Country
- China
- ProdList
- 3934
- Advantage
- 58
- Tel
- 15869524721
- 3525679403@qq.com
- Country
- China
- ProdList
- 4989
- Advantage
- 58
- Tel
- 027-59101668 19945030958
- Fax
- 027-59101668
- 2881924765@qq.com
- Country
- China
- ProdList
- 7937
- Advantage
- 58
- Tel
- 15071299552
- Fax
- QQ:262933239
- 262933239@qq.com
- Country
- China
- ProdList
- 7047
- Advantage
- 58
- Tel
- 13549236410
- sales@invivochem.cn
- Country
- China
- ProdList
- 6753
- Advantage
- 58
- Tel
- 13606124132;13656121842
- luyan0021@163.com
- Country
- China
- ProdList
- 235
- Advantage
- 58
- Tel
- 15387063101
- 2881924050@qq.com
- Country
- China
- ProdList
- 9959
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 0371-53370800 18037197114
- 2853031799@qq.com
- Country
- China
- ProdList
- 9892
- Advantage
- 58
- Tel
- 19307246857
- 2687203556@qq.com
- Country
- China
- ProdList
- 786
- Advantage
- 58
- Tel
- 18171815831
- 1341138380@qq.com
- Country
- China
- ProdList
- 4309
- Advantage
- 58
- Tel
- 18014399201
- sales@chemlab-tachizaki.com
- Country
- China
- ProdList
- 2742
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 0513-66337626 18051384581
- sales@chemhifuture.com
- Country
- China
- ProdList
- 5929
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 17316404525 17316404525
- 209533805@qq.com
- Country
- China
- ProdList
- 9766
- Advantage
- 58
- Tel
- 18221172427
- sale@fine-biotech.com
- Country
- China
- ProdList
- 2754
- Advantage
- 58
- Tel
- 400-821-026
- Sales@sangon.com
- Country
- China
- ProdList
- 6710
- Advantage
- 58
- Tel
- 13761144602
- 3896578657@qq.com
- Country
- China
- ProdList
- 4483
- Advantage
- 58
- Tel
- +8613720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 5221
- Advantage
- 58
- Tel
- +undefined15623860702
- info@chuchangbiotech.com
- Country
- China
- ProdList
- 202
- Advantage
- 58
- Tel
- --
- Fax
- --
- chenjw@absin.cn
- Country
- CHINA
- ProdList
- 6208
- Advantage
- 58
- Tel
- --
- Fax
- --
- Proteintech-CN@ptglab.com
- Country
- CHINA
- ProdList
- 6290
- Advantage
- 58
View Lastest Price from BMS-P5 manufacturers
- Product
- BMS-P5 1549811-36-0
- Price
- US $0.00-0.00/MG
- Min. Order
- 1MG
- Purity
- 98
- Supply Ability
- 100G
- Release date
- 2024-04-17